{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:59:36Z","timestamp":1789635576485,"version":"4.0.0"},"reference-count":39,"publisher":"Sociedade Brasileira de Cardiologia","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,24]]},"DOI":"10.36660\/abc.20230229","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T13:25:29Z","timestamp":1706621129000},"source":"Crossref","is-referenced-by-count":1,"title":["Diferen\u00e7as entre Duas Condi\u00e7\u00f5es Card\u00edacas Hipertr\u00f3ficas Distintas: Doen\u00e7a de Fabry Versus Cardiomiopatia Hipertr\u00f3fica"],"prefix":"10.36660","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4440-9599","authenticated-orcid":false,"given":"Onur","family":"Akhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0775-8992","authenticated-orcid":false,"given":"Mehmet","family":"K\u0131\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8470-1928","authenticated-orcid":false,"given":"Tuncay","family":"G\u00fczel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Zoghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22636","reference":[{"issue":"7","key":"key20240130082515_B1","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ejhf.1960","article-title":"An Expert Consensus Document on the Management of Cardiovascular Manifestations of Fabry Disease","volume":"22","author":"Linhart","year":"2020","unstructured":". Linhart A, Germain DP, Olivotto I, Akhtar MM, Anastasakis A, Hughes D, et al. An Expert Consensus Document on the Management of Cardiovascular Manifestations of Fabry Disease. Eur J Heart Fail. 2020;22(7):1076-96. doi: 10.1002\/ejhf.1960.","journal-title":"Eur J Heart Fail"},{"issue":"9647","key":"key20240130082515_B2","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry\u2019s Disease","volume":"372","author":"Zarate","year":"2008","unstructured":". Zarate YA, Hopkin RJ. Fabry\u2019s Disease. Lancet. 2008;372(9647):1427-35. doi: 10.1016\/S0140-6736(08)61589-5.","journal-title":"Lancet"},{"issue":"1","key":"key20240130082515_B3","doi-asserted-by":"crossref","first-page":"101439","DOI":"10.1016\/j.cpcardiol.2022.101439","article-title":"Cardiac Involvement in Fabry Disease and the Role of Multimodality Imaging in Diagnosis and Disease Monitoring","volume":"48","author":"Umer","year":"2023","unstructured":". Umer M, Motwani M, Jefferies JL, Nagueh SF, Kalra DK. Cardiac Involvement in Fabry Disease and the Role of Multimodality Imaging in Diagnosis and Disease Monitoring. Curr Probl Cardiol. 2023;48(1):101439. doi: 10.1016\/j.cpcardiol.2022.101439.","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"key20240130082515_B4","first-page":"19","article-title":"Diagnosis of Cardiovascular Involvement in Fabry Disease","volume":"24","author":"Citro","year":"2023","unstructured":". Citro R, Cristiano M, Radano I, Bellino M, Caiazza M, Galasso G, et al. Diagnosis of Cardiovascular Involvement in Fabry Disease. G Ital Cardiol. 2023;24(1):19-29. doi: 10.1714\/3934.39176.","journal-title":"G Ital Cardiol"},{"issue":"8-9","key":"key20240130082515_B5","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.acvd.2020.04.008","article-title":"The Value of Electrocardiography and Echocardiography in Distinguishing Fabry Disease from Sarcomeric Hypertrophic Cardiomyopathy","volume":"113","author":"Junqua","year":"2020","unstructured":". Junqua N, Legallois D, Segard S, Lairez O, R\u00e9ant P, Goizet C, et al. The Value of Electrocardiography and Echocardiography in Distinguishing Fabry Disease from Sarcomeric Hypertrophic Cardiomyopathy. Arch Cardiovasc Dis. 2020;113(8-9):542-50. doi: 10.1016\/j.acvd.2020.04.008.","journal-title":"Arch Cardiovasc Dis"},{"issue":"9","key":"key20240130082515_B6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/JCMA.0000000000000379","article-title":"Cardiac Manifestations in Patients with Classical or Cardiac Subtype of Fabry Disease","volume":"83","author":"Wang","year":"2020","unstructured":". Wang WT, Sung SH, Liao JN, Hsu TR, Niu DM, Yu WC. Cardiac Manifestations in Patients with Classical or Cardiac Subtype of Fabry Disease. J Chin Med Assoc. 2020;83(9):825-9. doi: 10.1097\/JCMA.0000000000000379.","journal-title":"J Chin Med Assoc"},{"issue":"3","key":"key20240130082515_B7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry Disease Defined: Baseline Clinical Manifestations of 366 Patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","unstructured":". Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, et al. Fabry Disease Defined: Baseline Clinical Manifestations of 366 Patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34(3):236-42. doi: 10.1111\/j.1365-2362.2004.01309.x.","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"key20240130082515_B8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10545-013-9659-2","article-title":"Prevalence of Fabry Disease in Male Patients with Unexplained Left Ventricular Hypertrophy in Primary Cardiology Practice: Prospective Fabry Cardiomyopathy Screening Study (FACSS)","volume":"37","author":"Palecek","year":"2014","unstructured":". Palecek T, Honzikova J, Poupetova H, Vlaskova H, Kuchynka P, Golan L, et al. Prevalence of Fabry Disease in Male Patients with Unexplained Left Ventricular Hypertrophy in Primary Cardiology Practice: Prospective Fabry Cardiomyopathy Screening Study (FACSS). J Inherit Metab Dis. 2014;37(3):455-60. doi: 10.1007\/s10545-013-9659-2.","journal-title":"J Inherit Metab Dis"},{"issue":"11","key":"key20240130082515_B9","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry Disease: Clinical Manifestations and Impact of Disease in a Cohort of 60 Obligate Carrier Females","volume":"38","author":"MacDermot","year":"2001","unstructured":". MacDermot KD, Holmes A, Miners AH. Anderson-Fabry Disease: Clinical Manifestations and Impact of Disease in a Cohort of 60 Obligate Carrier Females. J Med Genet. 2001;38(11):769-75. doi: 10.1136\/jmg.38.11.769.","journal-title":"J Med Genet"},{"issue":"2","key":"key20240130082515_B10","first-page":"139","article-title":"Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation","volume":"105","author":"Baptista","year":"2015","unstructured":". Baptista A, Magalh\u00e3es P, Le\u00e3o S, Carvalho S, Mateus P, Moreira I. Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation. Arq Bras Cardiol. 2015;105(2):139-44. doi: 10.5935\/abc.20150090.","journal-title":"Arq Bras Cardiol"},{"key":"key20240130082515_B11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.14744\/AnatolJCardiol.2022.2503","article-title":"The Frequency of Fabry Disease in Patients with Cardiac Hypertrophy of Various Phenotypes Including Prominent Papillary Muscle: The TUCARFAB Study in Turkey","author":"\u00d6zpelit","year":"2023","unstructured":". \u00d6zpelit E, \u00c7avu\u015fo\u011flu Y, Yorgun H, \u00d6k\u00e7\u00fcn E\u00d6B, Eker Ak\u0131ll\u0131 R, \u00c7elik A,  et al. The Frequency of Fabry Disease in Patients with Cardiac Hypertrophy of Various Phenotypes Including Prominent Papillary Muscle: The TUCARFAB Study in Turkey. Anatol J Cardiol. 2023;27(4):223-8. doi: 10.14744\/AnatolJCardiol.2022.2503.","journal-title":"Anatol J Cardiol"},{"issue":"1","key":"key20240130082515_B12","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-022-02599-w","article-title":"The Spanish Fabry Women Study: A Retrospective Observational Study Describing the Phenotype of Females with GLA Variants","volume":"18","author":"S\u00e1nchez","year":"2023","unstructured":". S\u00e1nchez R, Ripoll-Vera T, L\u00f3pez-Mendoza M, de Juan-Ribera J, Gimeno JR, Hermida \u00c1, et al. The Spanish Fabry Women Study: A Retrospective Observational Study Describing the Phenotype of Females with GLA Variants. Orphanet J Rare Dis. 2023;18(1):8. doi: 10.1186\/s13023-022-02599-w.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"key20240130082515_B13","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1002\/ehf2.14135","article-title":"Nationwide Screening of Fabry Disease in Patients with Hypertrophic Cardiomyopathy in Czech Republic","volume":"9","author":"Zem\u00e1nek","year":"2022","unstructured":". Zem\u00e1nek D, Janu\u0161ka J, Hon\u011bk T, \u010curila K, Kub\u00e1nek M, \u0160indel\u00e1\u0159ov\u00e1 \u0160,  et al. Nationwide Screening of Fabry Disease in Patients with Hypertrophic Cardiomyopathy in Czech Republic. ESC Heart Fail. 2022;9(6):4160-6. doi: 10.1002\/ehf2.14135.","journal-title":"ESC Heart Fail"},{"issue":"10","key":"key20240130082515_B14","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac Manifestations of Anderson-Fabry Disease: Results from the International Fabry Outcome Survey","volume":"28","author":"Linhart","year":"2007","unstructured":". Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, et al. Cardiac Manifestations of Anderson-Fabry Disease: Results from the International Fabry Outcome Survey. Eur Heart J. 2007;28(10):1228-35. doi: 10.1093\/eurheartj\/ehm153.","journal-title":"Eur Heart J"},{"issue":"39","key":"key20240130082515_B15","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Authors\/Task Force members","year":"2014","unstructured":". Authors\/Task Force membersElliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F,  et al. 2014 ESC Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-79. doi: 10.1093\/eurheartj\/ehu284.","journal-title":"Eur Heart J"},{"issue":"25","key":"key20240130082515_B16","first-page":"e558","article-title":"2020 AHA\/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"142","author":"Ommen","year":"2020","unstructured":". Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA\/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142(25):e558-e631. doi: 10.1161\/CIR.0000000000000937.","journal-title":"Circulation"},{"key":"key20240130082515_B17","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3750879","article-title":"Disparities in the Diagnosis of Hypertrophic Obstructive Cardiomyopathy: A Narrative Review of Current Literature","volume":"2018","author":"Burns","year":"2018","unstructured":". Burns J, Jean-Pierre P. Disparities in the Diagnosis of Hypertrophic Obstructive Cardiomyopathy: A Narrative Review of Current Literature. Cardiol Res Pract. 2018;2018:3750879. doi: 10.1155\/2018\/3750879.","journal-title":"Cardiol Res Pract"},{"issue":"1","key":"key20240130082515_B18","article-title":"Coronary Microvascular Dysfunction in Hypertrophic Cardiomyopathy: Pathophysiology, Assessment, and Clinical Impact","volume":"28","author":"Rosa","year":"2021","unstructured":". Rosa SA, Lopes LR, Fiarresga A, Ferreira RC, Carmo MM. Coronary Microvascular Dysfunction in Hypertrophic Cardiomyopathy: Pathophysiology, Assessment, and Clinical Impact. Microcirculation. 2021;28(1):e12656. doi: 10.1111\/micc.12656.","journal-title":"Microcirculation"},{"issue":"12","key":"key20240130082515_B19","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New Perspectives on the Prevalence of Hypertrophic Cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","unstructured":". Semsarian C, Ingles J, Maron MS, Maron BJ. New Perspectives on the Prevalence of Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249-54. doi: 10.1016\/j.jacc.2015.01.019.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"key20240130082515_B20","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1161\/CIR.0000000000000128","article-title":"AHA\/ACC\/HHS Strategies to Enhance Application of Clinical Practice Guidelines in Patients with Cardiovascular Disease and Comorbid Conditions: From the American Heart Association, American College of Cardiology, and US Department of Health and Human Services","volume":"130","author":"Arnett","year":"2014","unstructured":". Arnett DK, Goodman RA, Halperin JL, Anderson JL, Parekh AK, Zoghbi WA. AHA\/ACC\/HHS Strategies to Enhance Application of Clinical Practice Guidelines in Patients with Cardiovascular Disease and Comorbid Conditions: From the American Heart Association, American College of Cardiology, and US Department of Health and Human Services. Circulation. 2014;130(18):1662-7. doi: 10.1161\/CIR.0000000000000128.","journal-title":"Circulation"},{"issue":"17","key":"key20240130082515_B21","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1161\/CIR.0000000000000651","article-title":"Recent Innovations, Modifications, and Evolution of ACC\/AHA Clinical Practice Guidelines: An Update for Our Constituencies: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Levine","year":"2019","unstructured":". Levine GN, O\u2019Gara PT, Beckman JA, Al-Khatib SM, Birtcher KK, Cigarroa JE, et al. Recent Innovations, Modifications, and Evolution of ACC\/AHA Clinical Practice Guidelines: An Update for Our Constituencies: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(17):e879-e886. doi: 10.1161\/CIR.0000000000000651.","journal-title":"Circulation"},{"issue":"5","key":"key20240130082515_B22","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/echo.13829","article-title":"Comparison of Left Atrial Size and Function in Hypertrophic Cardiomyopathy and in Fabry Disease with Left Ventricular Hypertrophy","volume":"35","author":"Saccheri","year":"2018","unstructured":". Saccheri MC, Cianciulli TF, Licidio WC, Lax JA, Beck MA, Morita LA, et al. Comparison of Left Atrial Size and Function in Hypertrophic Cardiomyopathy and in Fabry Disease with Left Ventricular Hypertrophy. Echocardiography. 2018;35(5):643-50. doi: 10.1111\/echo.13829.","journal-title":"Echocardiography"},{"issue":"8","key":"key20240130082515_B23","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.12669\/pjms.38.8.7063","article-title":"Fabry Disease: Definition, Incidence, Clinical Presentations and Treatment - Focus on Cardiac Involvement","volume":"38","author":"Saeed","year":"2022","unstructured":". Saeed S, Imazio M. Fabry Disease: Definition, Incidence, Clinical Presentations and Treatment - Focus on Cardiac Involvement. Pak J Med Sci. 2022;38(8):2337-44. doi: 10.12669\/pjms.38.8.7063.","journal-title":"Pak J Med Sci"},{"issue":"6","key":"key20240130082515_B24","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.3390\/cells10061532","article-title":"Fabry Cardiomyopathy: Current Practice and Future Directions","volume":"10","author":"Yim","year":"2021","unstructured":". Yim J, Yau O, Yeung DF, Tsang TSM. Fabry Cardiomyopathy: Current Practice and Future Directions. Cells. 2021;10(6):1532. doi: 10.3390\/cells10061532.","journal-title":"Cells"},{"issue":"9","key":"key20240130082515_B25","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1080\/00015385.2022.2119670","article-title":"Evaluation of Demographic, Clinical, and Aetiological Data of Patients Admitted to Cardiology Clinics and Diagnosed with Left Ventricular Hypertrophy in Turkish Population (LVH-TR)","volume":"77","author":"Kis","year":"2022","unstructured":". Kis M, Dogan Y, Yildirim A, G\u00fczel T, Bekar L, Akhan O, et al. Evaluation of Demographic, Clinical, and Aetiological Data of Patients Admitted to Cardiology Clinics and Diagnosed with Left Ventricular Hypertrophy in Turkish Population (LVH-TR). Acta Cardiol. 2022;77(9):836-45. doi: 10.1080\/00015385.2022.2119670.","journal-title":"Acta Cardiol"},{"issue":"6","key":"key20240130082515_B26","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s10554-023-02826-w","article-title":"Prevalence of Fabry Disease in Patients with Left Ventricular Hypertrophy in Turkey: Multicenter Study (LVH-TR Subgroup Analysis)","volume":"39","author":"G\u00fczel","year":"2023","unstructured":". G\u00fczel T, \u00c7a\u011flar FNT, Ekici B, K\u0131\u015f M, \u00d6zta\u015f S, \u00d6z A,  et al. Prevalence of Fabry Disease in Patients with Left Ventricular Hypertrophy in Turkey: Multicenter Study (LVH-TR Subgroup Analysis). Int J Cardiovasc Imaging. 2023;39(6):1143-55. doi: 10.1007\/s10554-023-02826-w.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"6","key":"key20240130082515_B27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40265-021-01486-1","article-title":"Fabry Disease: The Current Treatment Landscape","volume":"81","author":"Lenders","year":"2021","unstructured":". Lenders M, Brand E. Fabry Disease: The Current Treatment Landscape. Drugs. 2021;81(6):635-45. doi: 10.1007\/s40265-021-01486-1.","journal-title":"Drugs"},{"issue":"3","key":"key20240130082515_B28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031887","article-title":"Chaperone Therapy in Fabry Disease","volume":"23","author":"Weidemann","year":"2022","unstructured":". Weidemann F, Jovanovic A, Herrmann K, Vardarli I. Chaperone Therapy in Fabry Disease. Int J Mol Sci. 2022;23(3):1887. doi: 10.3390\/ijms23031887.","journal-title":"Int J Mol Sci"},{"key":"key20240130082515_B29","doi-asserted-by":"crossref","DOI":"10.1177\/2054358120985627","article-title":"Renal Manifestations of Fabry Disease: A Narrative Review","volume":"8","author":"Silva","year":"2021","unstructured":". Silva CAB, Moura-Neto JA, Dos Reis MA, Vieira Neto OM, Barreto FC. Renal Manifestations of Fabry Disease: A Narrative Review. Can J Kidney Health Dis. 2021;8:2054358120985627. doi: 10.1177\/2054358120985627.","journal-title":"Can J Kidney Health Dis"},{"issue":"1","key":"key20240130082515_B30","article-title":"Risk of End-Stage Renal Disease in Patients with Hypertrophic Cardiomyopathy: A Nationwide Population-Based Cohort Study","volume":"9","author":"Lee","year":"2019","unstructured":". Lee H, Han K, Park JB, Hwang IC, Yoon YE, Park HE, et al. Risk of End-Stage Renal Disease in Patients with Hypertrophic Cardiomyopathy: A Nationwide Population-Based Cohort Study. Sci Rep. 2019;9(1):14565. doi: 10.1038\/s41598-019-50993-5.","journal-title":"Sci Rep"},{"key":"key20240130082515_B31","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2018.00108","article-title":"Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy","volume":"5","author":"Loso","year":"2018","unstructured":". Loso J, Lund N, Avanesov M, Muschol N, Lezius S, Cordts K, et al. Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy. Front Cardiovasc Med. 2018;5:108. doi: 10.3389\/fcvm.2018.00108.","journal-title":"Front Cardiovasc Med"},{"issue":"10","key":"key20240130082515_B32","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/clc.23425","article-title":"Correlations Between Cardiac Troponin I and Nonsustained Ventricular Tachycardia in Hypertrophic Obstructive Cardiomyopathy","volume":"43","author":"Liu","year":"2020","unstructured":". Liu L, Liu S, Shen L, Tu B, Hu Z, Hu F, et al. Correlations Between Cardiac Troponin I and Nonsustained Ventricular Tachycardia in Hypertrophic Obstructive Cardiomyopathy. Clin Cardiol. 2020;43(10):1150-9. doi: 10.1002\/clc.23425.","journal-title":"Clin Cardiol"},{"issue":"14","key":"key20240130082515_B33","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation","volume":"42","author":"Collet","year":"2021","unstructured":". Collet JP, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. Eur Heart J. 2021;42(14):1289-367. doi: 10.1093\/eurheartj\/ehaa575.","journal-title":"Eur Heart J"},{"key":"key20240130082515_B34","article-title":"Left Ventricular Strain Patterns and their Relationships with Cardiac Biomarkers in Hypertrophic Cardiomyopathy Patients with Preserved Left Ventricular Ejection Fraction","volume":"9","author":"Zhang","year":"2022","unstructured":". Zhang L, Wan Y, He B, Wang L, Zhu D, Gao F. Left Ventricular Strain Patterns and their Relationships with Cardiac Biomarkers in Hypertrophic Cardiomyopathy Patients with Preserved Left Ventricular Ejection Fraction. Front Cardiovasc Med. 2022;9:963110. doi: 10.3389\/fcvm.2022.963110.","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"key20240130082515_B35","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.mayocp.2022.08.010","article-title":"High-Sensitivity Cardiac Troponin T Elevation in Hypertrophic Cardiomyopathy is Associated with Ventricular Arrhythmias","volume":"98","author":"Burczak","year":"2023","unstructured":". Burczak DR, Newman DB, Jaffe AS, Ackerman MJ, Ommen SR, Geske JB. High-Sensitivity Cardiac Troponin T Elevation in Hypertrophic Cardiomyopathy is Associated with Ventricular Arrhythmias. Mayo Clin Proc. 2023;98(3):410-8. doi: 10.1016\/j.mayocp.2022.08.010.","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"key20240130082515_B36","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/eurheartj\/ehr021","article-title":"Prevalence and Clinical Correlates of QT Prolongation in Patients with Hypertrophic Cardiomyopathy","volume":"32","author":"Johnson","year":"2011","unstructured":". Johnson JN, Grifoni C, Bos JM, Saber-Ayad M, Ommen SR, Nistri S, et al. Prevalence and Clinical Correlates of QT Prolongation in Patients with Hypertrophic Cardiomyopathy. Eur Heart J. 2011;32(9):1114-20. doi: 10.1093\/eurheartj\/ehr021.","journal-title":"Eur Heart J"},{"key":"key20240130082515_B37","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijcard.2021.07.022","article-title":"ECG-Based Score Estimates the Probability to Detect Fabry Disease Cardiac Involvement","volume":"339","author":"Figliozzi","year":"2021","unstructured":". Figliozzi S, Camporeale A, Boveri S, Pieruzzi F, Pieroni M, Lusardi P, et al. ECG-Based Score Estimates the Probability to Detect Fabry Disease Cardiac Involvement. Int J Cardiol. 2021;339:110-7. doi: 10.1016\/j.ijcard.2021.07.022.","journal-title":"Int J Cardiol"},{"issue":"2","key":"key20240130082515_B38","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijcard.2014.09.001","article-title":"Uncertain Diagnosis of Fabry Disease: Consensus Recommendation on Diagnosis in Adults with Left Ventricular Hypertrophy and Genetic Variants of Unknown Significance","volume":"177","author":"Smid","year":"2014","unstructured":". Smid BE, van der Tol L, Cecchi F, Elliott PM, Hughes DA, Linthorst GE, et al. Uncertain Diagnosis of Fabry Disease: Consensus Recommendation on Diagnosis in Adults with Left Ventricular Hypertrophy and Genetic Variants of Unknown Significance. Int J Cardiol. 2014;177(2):400-8. doi: 10.1016\/j.ijcard.2014.09.001.","journal-title":"Int J Cardiol"},{"issue":"11","key":"key20240130082515_B39","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/eurheartj\/ehs166","article-title":"Left Ventricular Hypertrophy in Fabry Disease: A Practical Approach to Diagnosis","volume":"34","author":"Yousef","year":"2013","unstructured":". Yousef Z, Elliott PM, Cecchi F, Escoubet B, Linhart A, Monserrat L, et al. Left Ventricular Hypertrophy in Fabry Disease: A Practical Approach to Diagnosis. Eur Heart J. 2013;34(11):802-8. doi: 10.1093\/eurheartj\/ehs166.","journal-title":"Eur Heart J"}],"container-title":["Arquivos Brasileiros de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/abccardiol.org\/article\/diferencas-entre-duas-condicoes-cardiacas-hipertroficas-distintas-doenca-de-fabry-versus-cardiomiopatia-hipertrofica\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T13:15:00Z","timestamp":1747401300000},"score":1,"resource":{"primary":{"URL":"https:\/\/abccardiol.org\/article\/diferencas-entre-duas-condicoes-cardiacas-hipertroficas-distintas-doenca-de-fabry-versus-cardiomiopatia-hipertrofica\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,24]]}},"alternative-id":["10.36660\/abc.20230229"],"URL":"https:\/\/doi.org\/10.36660\/abc.20230229","relation":{},"ISSN":["0066-782X","1678-4170"],"issn-type":[{"value":"0066-782X","type":"print"},{"value":"1678-4170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"e20230229"}}